Overview
Endocervical adenocarcinoma (EA) is a malignant neoplasm arising from the glandular cells of the endocervix, exhibiting diverse pathogenic mechanisms beyond traditional morphologic classification. Recent advancements propose the International Endocervical Adenocarcinoma Criteria and Classification (IECC) to better reflect these complexities 1.Diagnosis
Key Diagnostic Criteria: Architectural patterns, including haphazard proliferation of glands and focal cytologic atypia, are crucial 3.
Recommended Tests: Hematoxylin and eosin (H&E) staining supplemented by immunohistochemistry (IHC) for markers like p16, PR, p53, Napsin-A, vimentin, CDX2, and GATA3 enhances diagnostic accuracy 1.
Grading: IECC shows superior interobserver agreement compared to WHO criteria, particularly with IHC support 1.
Distinguishing Features: Minimal deviation adenocarcinoma (MDA) mimics normal endocervical glandular patterns but requires focal cytoplasmic carcinoembryonic antigen (CEA) expression for differentiation from benign lesions 3.Management
First-Line Treatment: Surgical resection (e.g., radical hysterectomy) is typically the primary approach, especially for early-stage disease 3.
Adjuvant Therapy: Adjuvant radiation therapy may be considered based on stage, lymph node involvement, and histologic grade 3.
Immunohistochemistry: Use of IHC markers aids in refining diagnosis and guiding treatment decisions 13.Special Populations
Pregnancy: Specific management strategies for EA during pregnancy are not detailed in the provided abstracts [].
Pediatrics: No specific data on pediatric cases of EA are presented [].
Elderly: Considerations for elderly patients include tailored surgical approaches and potential comorbidities affecting treatment tolerance [].
Comorbidities: Management should account for coexisting conditions impacting surgical risk and adjuvant therapy feasibility [].Key Recommendations
Utilize the International Endocervical Adenocarcinoma Criteria and Classification (IECC) for improved diagnostic reproducibility over WHO criteria, especially with immunohistochemical support (Evidence: Strong 1).
Incorporate immunohistochemical staining, particularly for CEA, to differentiate minimal deviation adenocarcinoma from benign lesions (Evidence: Moderate 3).
Employ surgical resection as the primary treatment modality for EA, complemented by adjuvant therapies based on staging and histologic features (Evidence: Expert opinion []).References
1 Hodgson A, Park KJ, Djordjevic B, Howitt BE, Nucci MR, Oliva E et al.. International Endocervical Adenocarcinoma Criteria and Classification: Validation and Interobserver Reproducibility. The American journal of surgical pathology 2019. link
2 Fetissof F, Jobard P, Arbeille-Brassart B, Dubois MP, Lansac J, Sam-Giao M. Unusual endocervical polypoid tumor with endocrine cells: an immunohistochemical and ultrastructural analysis. Ultrastructural pathology 1986. link
3 Michael H, Grawe L, Kraus FT. Minimal deviation endocervical adenocarcinoma: clinical and histologic features, immunohistochemical staining for carcinoembryonic antigen, and differentiation from confusing benign lesions. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 1984. link